LEXURIS

Welcome to the Brand page for “LEXURIS”, which is offered here for Pharmaceutical preparations used for the treatment of cancer, pharmaceutical preparations administered as a radiosensitizer and used for the treatment of cancer, pharmaceutical preparations used for the treatment of urological diseases, pharmaceutical preparations used for the treatment of hormonal disorders, peptides-containing pharmaceutical preparations used for hormonal and tumors treatments, pharmaceutical preparations used for the treatment of endocrine diseases, pharmaceutical preparations used for the treatment of carcinoid tumors, pharmaceutical preparations used for the treatment of age-related diseases, pharmaceutical preparation used for the treatment of endometriosis, pharmaceutical preparations used for the treatment of uterine myoma, pharmaceutical preparations used for the treatment of non-malignant tumors, pharmaceutical preparation used for the treatment for benign prostatic hyperplasia (bph), pharmaceutical preparations used as a tubulin inhibitor, pharmaceutical preparations based on lhrh antagonists platform for the treatment of cancer, cancer in combination with administered radiosensitizing, urological diseases, hormonal disorders, hormonal and tumor disorders, endocrine diseases,carcinoid tumors, age-related diseases, endometriosis, uterine myoma, non-malignant tumors and benign prostatic hyperplasia; pharmaceutical preparations used to induce apoptosis;.

Its status is currently believed to be active. Its class is unavailable. “LEXURIS” is believed to be currently owned by “AETERNA ZENTARIS GMBH”.